RAS

[Auris Medical Holding Ltd.] Auris Medical Holding Ltd. announced the selection of mutant KRAS-driven colorectal cancer as the first therapeutic indication for its OligoPhore™ oligonucleotide delivery platform, based on outcomes from studies with OligoPhore™ enabled KRAS silencing, and a well-defined regulatory and development pathway.

[Trends in Molecular Medicine] Several regenerative approaches involving the delivery of reparative cells or products have achieved kidney repair in experimental models of renal artery stenosis (RAS) and the delivery of mesenchymal stem/stromal cells has already been translated to human subjects with RAS with promising results.

[Nature Communications] The authors showed that persistent oncogenic RAS signaling caused highly metastatic triple-negative mammary tumors in mice. The continuous signaling of oncogenic RAS played a crucial role in the cellular plasticity and maintenance of the mesenchymal and stem cell characteristics of claudin-low mammary cancer cells.

[Journal of Nanobiotechnology] To dissect the mechanism of a combined tumoricidal therapeutic strategy, scientists investigated the scRNA-seq transcriptional profiles of an hepatocellular carcinoma xenograft following treatment.

[Scientific Reports] Scientists found that acrolein induced oncogenic transformation, including faster cell cycling, proliferation, sphere formation and cell migration, in fibroblast cells, and acrolein-induced DNA damages were higher in colorectal cancer (CRC) tumor tissues than in normal epithelial cells in CRC patients.

[Blood] Investigators discovered that FLT3-ITD, one of the most frequent mutations in acute myeloid leukemia, was S-palmitoylated by the ZDHHC6 palmitoyl acyltransferase. Disruption of palmitoylation redirected FLT3-ITD to the plasma membrane and rewired its downstream signaling by activating AKT and ERK pathways in addition to STAT5.